Astellas Pharma Inc. Partners With CUOG to Advance Uro-Oncology Research in Canada

Published: Apr 17, 2013

MARKHAM, ON, April 17, 2013 /CNW/ - Genitourinary cancer research in Canada will receive additional funding thanks to a new research collaboration between the Canadian Urologic Oncology Group (CUOG) and Astellas Pharma Canada, Inc. (Astellas). This year, Astellas has pledged $50,000 to further Canadian investigators' peer-reviewed research into finding medicines and cures for urological disorders, focusing specifically on prostate cancer.

Back to news